• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by T2 Biosystems Inc. (Amendment)

    5/13/24 7:21:56 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care
    Get the next $TTOO alert in real time by email
    SC 13D/A 1 d838783dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    T2 Biosystems, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    89853L302

    (CUSIP Number)

    Andrei Dorenbaum

    c/o CR Group L.P.

    1000 Main Street, Suite 2500

    Houston, TX 77002

    (703) 209-7350

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 9, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     


    CUSIP No. 89853L302       Page 2 of 10

     

     1.    

     Names of Reporting Persons

     

     Nathan D. Hukill

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     10,677,973

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     10,677,973

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     10,677,973

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     69.5% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 3 of 10

     

     1.    

     Names of Reporting Persons

     

     CR Group L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     10,677,973

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     10,677,973

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     10,677,973

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     69.5% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     IA

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 4 of 10

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     1,330,175

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     1,330,175

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,330,175

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     8.7% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 5 of 10

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III – Parallel Fund “A” L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     828,324

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     828,324

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     828,324

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     5.4% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 6 of 10

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III (Cayman) Unlev AIV I L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     266,038

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     266,038

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     266,038

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     1.7% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 7 of 10

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III (Cayman) Lev AIV I L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     3,548,707

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     3,548,707

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,548,707

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     23.1% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 8 of 10

     

     1.    

     Names of Reporting Persons

     

     CRG Partners III Parallel Fund “B” (Cayman) L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒ (1)  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO (2)

     5.  

     Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     4,704,729

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     4,704,729

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,704,729

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     30.6% (3)

    14.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

    (2)

    The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

    (3)

    This percentage is calculated based on 15,366,085 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer, plus 1,716,048 shares of Common Stock issued upon conversion of Series A Convertible Preferred Stock and 108,752 shares of Common Stock issued upon conversion of shares of Series B Convertible Preferred Stock on May 9, 2024. The shares of Series A Convertible Preferred Stock and the shares of Series B Convertible Preferred Stock were held by CRG Partners III Parallel Fund “B” (Cayman) L.P.


    CUSIP No. 89853L302       Page 9 of 10

     

    Explanatory Note

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D supplements and amends the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on April 19, 2024, as amended by the Amendment No. 1 to Schedule 13D originally filed with the SEC on May 7, 2024 (together, as so amended, the “Schedule 13D”) jointly by each of the following persons (collectively, the “Reporting Persons”): Nathan D. Hukill (“Mr. Hukill”), a citizen of the United States, CR Group L.P., a Delaware limited partnership (“CR Group”), CRG Partners III – Parallel Fund “A” L.P., a Delaware limited partnership (“CRG Parallel Fund A”), CRG Partners III (Cayman) Unlev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Unlev AIV”), CRG Partners III (Cayman) Lev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Lev AIV”), and CRG Partners III Parallel Fund “B” (Cayman) L.P., a Cayman Islands exempted limited partnership (“CRG Parallel Fund B” and collectively with CRG Parallel Fund A, CRG Unlev AIV and CRG Lev AIV, the “CRG Funds”). Except as otherwise specified in this Amendment No. 2, all items in the Schedule 13D remain unchanged. All capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Schedule 13D.

    The Reporting Persons are filing this Amendment No. 1 to report certain changes in their beneficial ownership of the common stock, par value $0.001 per share (the “Common Stock”), of T2 Biosystems, Inc., a Delaware corporation (the “Issuer”) as result of certain transactions in Common Stock of the Issuer.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    The response to Item 3 in the Schedule 13D is hereby amended and restated as follows:

    The information set forth in Items 5 and 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 3.

    All of the shares reported on this Schedule 13D were acquired from the Issuer in exchange for the Reporting Persons’ cancellation of outstanding loans to the Issuer under that certain Term Loan Agreement, dated as of December 30, 2016, as amended, by and among the Issuer and CRG Servicing LLC, as administrative agent and collateral agent, and the lenders named therein. The most recent acquisitions occurred on April 12, 2024, May 3, 2024 and May 9, 2024. Refer to the Issuer’s current reports on Form 8-K filed on July 6, 2023, February 15, 2024, April 18, 2024 and May 6, 2024 for additional information.

     

    Item 5.

    Interest in Securities of the Issuer

    The response to Item 5 in the Schedule 13D is hereby amended and restated as follows:

    The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2 and 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

    By virtue of the relationships among the Reporting Persons described herein, the Reporting Persons may be deemed to constitute a group within the meaning of Section 13(d)(5) of the rules and regulations promulgated by the Securities and Exchange Commission pursuant to the Exchange Act. As such, pursuant to Rule 13d-3 under the Exchange Act, such group may be deemed to beneficially own an aggregate of 10,677,973 shares of Common Stock, representing in the aggregate approximately 69.5% of the issued and outstanding shares of Common Stock, as calculated pursuant to Rule 13d-3 under the Exchange Act.

    Except as set forth in this Schedule 13D, none of the Reporting Persons has effected any transactions in Common Stock during the last 60 days.

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    Item 7.

    Material to be Filed as Exhibits

    Joint Filing Agreement*

    *

    Previously filed.


    CUSIP No. 89853L302       Page 10 of 10

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: May 13, 2024

     

    Nathan D. Hukill

    /s/ Nathan D. Hukill

    An individual
    CR Group L.P.
    CRG Partners III L.P.
    CRG Partners III – Parallel Fund “A” L.P.
    CRG Partners III (Cayman) Unlev AIV I L.P.
    CRG Partners III (Cayman) Lev AIV I L.P.
    CRG Partners III Parallel Fund “B” (Cayman) L.P.
    By:  

    /s/ Nathan D. Hukill

      Nathan D. Hukill, authorized signatory
    Get the next $TTOO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTOO

    DatePrice TargetRatingAnalyst
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $TTOO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

      LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including

      1/7/25 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

      LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st

      12/18/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

      LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (

      12/17/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/14/24 3:38:45 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:02:19 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:01:48 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • T2 Biosystems upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

      2/18/22 10:16:52 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

      Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously

      3/5/21 7:31:44 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems downgraded by Alliance Global Partners with a new price target

      Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously

      1/27/21 8:12:03 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    SEC Filings

    See more
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/4/25 5:47:15 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by T2 Biosystems Inc.

      NT 10-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/1/25 9:00:30 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      2/20/25 9:00:24 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Financials

    Live finance-specific insights

    See more
    • T2 Biosystems Announces Third Quarter 2024 Financial Results

      LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar

      11/14/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

      LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320

      11/5/24 8:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Host Business Update Call on October 10, 2024

      LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the

      10/8/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Liebman Seymour

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:58:44 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:55:13 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Adams Laura Lee

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:46:12 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

      LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2

      11/4/21 4:04:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Appoints Laura Adams to Its Board of Directors

      LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead

      10/19/21 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care